Venenum BioDesign, LLC的动态

Very much benefited from the information provided in the webinar. Although the cost penalty per day has seemingly gone down it can still have significant financial impact should the length go weeks or month without resolution. At Ubuntu Research we work with our clients to directly increase operating efficiency and reduce cost. By leveraging our unique approach, we trim development timelines from IND to BLA by up to 20%, which directly translates to enhanced eNPVs and reduced financing burdens. https://lnkd.in/eky3cw4S

?? Mark your calendars! The BMCS 4th Synthesis in Drug Discovery and Development 2024 is just around the corner. ?? June 4-5, 2024 ?? Virtual meeting Do not miss out this virtual symposium exploring the vital role of synthesis in drug discovery and development! Registration deadline: June 3rd, 2024 ?? https://lnkd.in/ebTH8NiX #BMCS #SDDD24 #DrugDiscovery #VirtualEvent

Announcing the Illuminate Hypersomnia Adjunct Scientific Meeting happening February 13, 2025, from 12:00 – 2:00 p.m. EST. This virtual scientific session features leading global experts in the idiopathic hypersomnia (IH) field and aims to address critical challenges in drug development for IH. The agenda focuses on priorities identified by the IH patient community through the groundbreaking Illuminate Hypersomnia Externally Led Patient-Focused Drug Development meeting and survey. Learn more and register for the meeting at https://lnkd.in/ezvDE-vr. #IHPFDD #IlluminateIH #idiopathichypersomnia #livingwithIH #livingwithidiopathichypersomnia #idiopathichypersomnolence #PFDD #patientfocused #sleepconsortium #thisisIH

Innovative approaches to clinical trials to improve the efficiency of drug development is the way forward. Some of the focuses in the pipeline include:- 1) point-of-care or pragmatic trials; 2) Bayesian analyses; and 3) trials using selective safety data collection.

? Comparing the US & Europe Clinical Trial Landscapes ? Ahead of next week's COG New England, I sat down with Gary Quashie, of OPIS to discuss the challenges faced by #biopharma trial sponsors, as well as drawing comparisons from the European environment for #clinicaltrials. Key highlights from our discussion included: ?? Patient-centric trials have shown faster enrolment and initiation, emphasising the importance of including #patientadvocacy groups and CROs early in #protocoldevelopment ?? The US remains the top location for #clinicalresearch due to the FDA's robust framework, NIH support, renowned medical institutes, and a large, diverse patient population ?? The number of US trials are declining, China has seen a steady increase in recent years, though political impact is yet to be seen ?? Europe can be faster and more cost-effective for running studies, with strong Key Opinion Leader advocates and the streamlined European Clinical Trials Information System (#CTIS) regulatory process ?? Sponsors should partner with experienced CROs, leverage patient diversity plans, carefully assess #sitefeasibility, and embrace #patientcentric approaches and emerging technologies to navigate the evolving clinical trials landscape Read in full below ?? & meet Gary at COG New England next week!

At Least 15 Generic Versions of Ozempic Are in Clinical Trials in China

The University of Florida, Clinical & Translational Science Institute (CTSI) Investigational Drug Service faced significant operational challenges due to manual, paper-based processes. By adopting Vestigo?, they achieved remarkable efficiency and compliance improvements. Key achievements: ? 51.7% increase in protocol count ? 43% boost in revenue ? Improved staff efficiency and compliance Learn more about their journey and the measurable impact of Vestigo? in this success story: https://hubs.ly/Q032WKQ70 #ClinicalResearch #OperationalEfficiency #Innovation #Vestigo #Healthcare

?? Missed the new ENETS-NANETS-Webinar: Highlights of PRRT and drug development abstracts? Now you can watch the video recording from the most prominent NEN experts from Europe and USA on clinical trials updates related to GEP NETs and #pheochromocytomas/#paragangliomas. ? Watch here: https://lnkd.in/dbDUuedg #LetsTalkAboutNETs #NeuroendocrineCancer?

Assessing the likelihood of the success of a new pharmaceutical treatment requires context. Learn more about one way to look at that contextual information at the link below.